CorMedix Inc. Earnings Recaps
Q1 2026
May 15, 2026
CorMedix shares gained 5.7% following Q1 results that beat expectations on net revenue and adjusted EBITDA, leading the company to raise full-year guidance across key metrics including DefenCath sales despite anticipated reimbursement variability in the second half of the year.
Key takeaways
- Q1 net revenue reached $127.4 million, significantly above prior consensus.
- Adjusted EBITDA totaled $70 million, prompting an increase in full year guidance to $115 million–$135 million from a prior $100 million–$125 million range.
- Full-year net revenue guidance was raised to $325 million–$345 million, up from $300 million–$320 million, driven by strong early performance and sustained DefenCath demand.
- DefenCath full-year guidance increased to $175 million–$195 million, reflecting robust utilization despite the expiration of initial TDAPA reimbursement and transition to post-TDAPA add-on pricing in H2 2026.
- The company announced positive top-line clinical data for REZZAYO, supporting upcoming FDA sNDA submission and potential 2027 launch, with planned commercial infrastructure investments in the latter half of 2026.
Q3 2025
Nov 12, 2025
CorMedix delivered its strongest financial quarter to date, bolstered by the transformational acquisition of Melinta Therapeutics, driving record revenue and substantial EBITDA growth.
Key takeaways
- Achieved record revenue of $104.3 million and net income of $108.6 million, significantly enhancing financial performance.
- Raised full year revenue guidance from $375 million to a range of $390 million to $410 million, reflecting strong market momentum.
- Announced a strategic minority investment in Talphera Inc., positioning CorMedix for expansion into critical care.
- Integration of Melinta operations ahead of schedule, with expected synergies of $30 million from a total of $35-$45 million by late 2025.
- Upcoming catalysts include pivotal Phase III data for Rezzayo in invasive fungal infection prophylaxis and expansion of DefenCath to prevent CLABSI in TPN patients.